These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 79108)

  • 1. 1alpha-hydroxy derivatives of vitamin D3 and renal function.
    Kanis JA; Cundy T; Naik R
    Lancet; 1978 Aug; 2(8084):316-7. PubMed ID: 79108
    [No Abstract]   [Full Text] [Related]  

  • 2. Impairment of renal function in patients on 1alpha-hydroxycholecalciferol.
    Winterborn MH; Mace PJ; Heath DA; White RH
    Lancet; 1978 Jul; 2(8081):150-1. PubMed ID: 78344
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal osteodystrophy. Effect of hemodialysis and 1 alpha-hydroxy vitamin D3 on bone lesions and metacarpal bone mass.
    Andresen J; Nielsen HE; Johannsen A
    Acta Radiol Diagn (Stockh); 1980; 21(4):541-4. PubMed ID: 7457184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deterioration of renal function in non-dialytic uraemics caused by 1 alpha (OH)D3 which was not attributable to hypercalcaemia.
    Yoshiyama N; Akiba T; Matsui N; Iwamoto H; Ogura M; Nakagawa S; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1980; 17():569-74. PubMed ID: 7243799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.
    Christiansen C; Rødbro P; Christensen MS; Hartnack B; Transbøl I
    Lancet; 1978 Sep; 2(8092 Pt 1):700-3. PubMed ID: 80633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin-D analogues and renal function.
    Christiansen C; Christensen MS; Hartnack B; Melsen F; Transbøl I; Rødbro P
    Lancet; 1979 Jan; 1(8106):50-1. PubMed ID: 83502
    [No Abstract]   [Full Text] [Related]  

  • 7. Cessation of bone loss in chronic renal failure by 1-alpha-hydroxyvitamin D3: a controlled trial.
    Madsen S; Olgaard K; Ladefoged J
    Proc Eur Dial Transplant Assoc; 1978; 15():517-23. PubMed ID: 311003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment of renal function in patients on 1alpha-hydroxycholecalciferol.
    Lancet; 1978 Aug; 2(8086):427-8. PubMed ID: 79789
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of alfacalcidol in the prevention of bone disease in early renal failure.
    Kanis JA
    Nephrol Dial Transplant; 1995; 10 Suppl 4():23-8; discussion 37-43. PubMed ID: 7478146
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperparathyroidism and the predictability of response to 1alpha-hydroxyvitamin D3.
    Bone JM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():83s-84s. PubMed ID: 606429
    [No Abstract]   [Full Text] [Related]  

  • 11. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1 alpha-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function.
    Nielsen HE; Rømer FK; Melsen F; Christensen MS; Hansen HE
    Clin Nephrol; 1980 Mar; 13(3):103-8. PubMed ID: 7379358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in vitamin D metabolism as they pertain to chronic renal disease.
    Coburn JW; Hartenbower DL; Brickman AS
    Am J Clin Nutr; 1976 Nov; 29(11):1283-99. PubMed ID: 187055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment with 1-alpha hydroxy vitamin D3 of bone disease in hemodialysis. Therapeutic results and complications].
    García de Vinuesa S; Barril G; Luño J; Alles A; Jofré R; Pérez García R; Olivas E; López Gómez JM; Valderrábano F
    Rev Clin Esp; 1980 Dec; 159(5):317-22. PubMed ID: 7221095
    [No Abstract]   [Full Text] [Related]  

  • 15. Proceedings: The use of metabolically-active derivatives of vitamin D in rickets and osteomalacia due to renal glomerular failure.
    Smith R; Henderson RG; Russell RG
    J Bone Joint Surg Br; 1975 May; 57(2):247-8. PubMed ID: 1141297
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of 1 alpha-(OH)D3 on renal osteodystrophy--a 5-year retrospective evaluation].
    Kakuhara T; Mizoguchi M; Itoh M; Nagasawa M; Mori T; Ohtsuka K; Kubota M; Minatoguchi T; Ohara K; Yoshida M; Koide H; Ohno J
    Nihon Jinzo Gakkai Shi; 1982 Jun; 24(6):693-704. PubMed ID: 7176180
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of renal bone disease.
    Lancet; 1979 Dec 22-29; 2(8156-8157):1339-40. PubMed ID: 92678
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of vitamin D 2 and its metabolites in chronic glomerulonephritis in children].
    Naumova VI; Rusnak FI; Vereskova SA; Kutafina EK; Panchenko EL
    Pediatriia; 1989; (5):19-22. PubMed ID: 2671919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.